{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Leukaemia&page=2",
    "query": {
      "condition": "Acute Leukaemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Leukaemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T22:28:04.355Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05776134",
      "title": "Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel",
      "overall_status": "AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Mantle Cell Lymphoma",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Brexucabtagene Autoleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05776134"
    },
    {
      "nct_id": "NCT06846606",
      "title": "Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed Acute Myeloid Leukemia (AML)",
        "Refractory Acute Myeloid Leukemia (AML)",
        "Relapsed/Refractory AML",
        "Relapsed Myelodysplastic Syndromes",
        "Refractory Myelodysplastic Syndromes",
        "Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "AUTX-703",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Auron Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2025-05-01",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-03-03",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 9,
      "location_summary": "Duarte, California • Tampa, Florida • Buffalo, New York + 6 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06846606"
    },
    {
      "nct_id": "NCT06811233",
      "title": "Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "DMSA",
          "type": "DRUG"
        },
        {
          "name": "Ca-EDTA",
          "type": "DRUG"
        },
        {
          "name": "Magnesium Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Multivitamin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2025-05-08",
      "completion_date": "2031-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06811233"
    },
    {
      "nct_id": "NCT04139434",
      "title": "Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "AML/MDS",
        "CMML",
        "Relapse",
        "Refractory Acute Lymphoblastic Leukemia",
        "Relapse Leukemia",
        "Relapsed Adult AML"
      ],
      "interventions": [
        {
          "name": "LP-108",
          "type": "DRUG"
        },
        {
          "name": "LP-108 and azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newave Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2020-07-06",
      "completion_date": "2025-12-19",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 4,
      "location_summary": "Ann Arbor, Michigan • Cincinnati, Ohio • Columbus, Ohio + 1 more",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Huston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04139434"
    },
    {
      "nct_id": "NCT01012492",
      "title": "Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML",
        "ALL",
        "Undifferentiated Leukemia",
        "Biphenotypic Leukemia",
        "Refractory Anemia",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Ref. Cytopenia w Multilineage Dysplasia & Ringed Sideroblasts",
        "Refractory Anemia With Excess Blasts-1 (5-10% Blasts)",
        "Refractory Anemia With Excess Blasts-2 (10-20% Blasts)",
        "Myelodysplastic Syndrome, Unclassified",
        "MDS Associated With Isolated Del (5q)"
      ],
      "interventions": [
        {
          "name": "Abatacept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2009-11",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2019-11-21",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01012492"
    },
    {
      "nct_id": "NCT01130506",
      "title": "Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Previously Treated Myelodysplastic Syndrome",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Decitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 17,
      "start_date": "2010-05-17",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-08-02",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 2,
      "location_summary": "Columbus, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01130506"
    },
    {
      "nct_id": "NCT00723099",
      "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Aggressive Non-Hodgkin Lymphoma",
        "Chronic Myelogenous Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Indolent Non-Hodgkin Lymphoma",
        "Lymphoma",
        "Mixed Phenotype Acute Leukemia",
        "Myelodysplastic Syndrome",
        "Myeloproliferative Neoplasm",
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Follicular Lymphoma",
        "Recurrent Lymphoplasmacytic Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent T-Cell Non-Hodgkin Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Chronic Myelogenous Leukemia",
        "Refractory Follicular Lymphoma",
        "Refractory Hodgkin Lymphoma",
        "Refractory Lymphoplasmacytic Lymphoma",
        "Refractory Mantle Cell Lymphoma",
        "Refractory Small Lymphocytic Lymphoma",
        "T-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 73,
      "start_date": "2008-06-25",
      "completion_date": "2018-07-31",
      "has_results": true,
      "last_update_posted_date": "2019-12-27",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Salt Lake City, Utah + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00723099"
    },
    {
      "nct_id": "NCT02380222",
      "title": "Patient-Reported Outcome Questionnaire for Systemic Mastocytosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Aggressive Systemic Mastocytosis (ASM)",
        "SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)",
        "Mast Cell Leukemia (MCL)",
        "Smoldering Systemic Mastocytosis (SSM)",
        "Indolent Systemic Mastocytosis (ISM) ISM Subgroup Fully Recruited"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Adelphi Values LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2014-07",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-10",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02380222"
    },
    {
      "nct_id": "NCT03349281",
      "title": "Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Acute Lymphoblastic Leukemia",
        "Relapsed Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Pevonedistat",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "PEG-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Julio Barredo, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "16 Years to 39 Years"
      },
      "enrollment_count": 6,
      "start_date": "2019-03-25",
      "completion_date": "2022-10-12",
      "has_results": false,
      "last_update_posted_date": "2022-10-20",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03349281"
    },
    {
      "nct_id": "NCT02793544",
      "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chemotherapy-sensitive Lymphoma",
        "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Biphenotypic Leukemia (ABL)",
        "Acute Undifferentiated Leukemia (AUL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy on Day -1",
          "type": "RADIATION"
        },
        {
          "name": "Infusion of non-T-cell depleted bone marrow on Day 0",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1",
          "type": "RADIATION"
        },
        {
          "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -6 and -5",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -2 and -1",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -5 and -4",
          "type": "DRUG"
        },
        {
          "name": "Post-HCT Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-12",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-07-23T22:28:04.355Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793544"
    }
  ]
}